Production (Stage)
Kyverna Therapeutics, Inc.
KYTX
$3.20
-$0.195-5.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -145.42M | -127.48M | -110.66M | -76.16M | -47.36M |
| Total Depreciation and Amortization | 2.15M | 2.13M | 2.03M | 1.47M | 944.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.12M | 3.24M | 4.04M | 2.85M | 3.16M |
| Change in Net Operating Assets | 7.51M | 7.86M | 8.83M | 3.58M | -829.00K |
| Cash from Operations | -133.64M | -114.25M | -95.75M | -79.40M | -55.22M |
| Capital Expenditure | -1.66M | -2.21M | -2.01M | -1.91M | -877.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.78M | -158.70M | -156.44M | -157.21M | -90.32M |
| Cash from Investing | -32.45M | -160.90M | -158.44M | -213.24M | -145.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.07M | -956.00K | -928.00K | -686.00K | -450.00K |
| Issuance of Common Stock | 198.00K | 341.43M | 341.67M | 341.58M | 341.51M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -482.00K | -3.36M | -4.85M | -4.85M | -4.45M |
| Cash from Financing | -1.35M | 337.11M | 335.89M | 370.84M | 371.41M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -167.44M | 61.96M | 81.70M | 78.20M | 170.87M |